Trial Profile
A phase I/II study of PTK787 [vatalanib] in combination with trastuzumab in patients with newly diagnosed HER2 overexpressing locally recurrent or metastatic breast cancer: Hoosier Oncology Group Trial BRE04-80
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Vatalanib (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2007 Patient numbers amended from 37 to 7
- 01 Nov 2007 Status changed from in progress to suspended.
- 27 Nov 2005 New trial record.